According to the OECD Economic Survey of Switzerland in 2019, the population aged between 65 years or more than this is expected to rise by 30 percent by the year 2050 and the population of 80 years is anticipated to double by 2045. With the growing age comes a common surge in the number of aging patients because of the increasing chronic disease prevalence. Age is a severe risk factor for disease progression affecting fundamental biological mechanisms. Thus, aging is one of the risk factors for the global incidence of early age-related macular degeneration (AMD) disease and is expected to increase the global age-related macular degeneration (AMD) disease growth.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-age-related-macular-degeneration-amd-disease-market
Data Bridge Market Research analyses a growth rate in the Global Age-Related Macular Degeneration (AMD) Disease Market is expected to reach USD 3.08 billion by 2030 from USD 1.81 billion in 2022, growing at a CAGR of 6.90% in the forecast period of 2023 to 2030. Increasing awareness and treatment-seeking rates will likely increase the growth of the global age-related macular degeneration (AMD) disease market.
The increasing prevalence of age-related macular degeneration is expected to drive the market's growth rate
The prevalence of vision-threatening diseases, such as age-related macular degeneration glaucoma, cataract, is expected to rise in developed countries because of increasing life expectancy and aging population. For instance, as per the article published by National Center for Biotechnology Information, In 2020, the total number of people affected by any age-related macular degeneration (AMD) disease was around 67 million people in Europe because of population aging. This number is anticipated to surge by 15 percent until 2050. Thus, the growing prevalence of age-related macular degeneration (AMD) is anticipated to drive the growth of the market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015- 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Loop Road Holdings LLC (U.S.), Old Saw Mill Holdings LLC (U.S.), OSMR LLC (U.S.), Regeneron Capital International B.V. (Netherlands) and Regeneron International Limited (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland)., Bayer AG (Germany), Abbvie, Inc (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The age-related macular degeneration (AMD) disease market is segmented on the basis of type, end user and distribution channel.
- Based on type, the global age-related macular degeneration (AMD) disease market is segmented into dry age-related macular degeneration and wet age-related macular degeneration.
The dry age-related macular degeneration segment of type segment is anticipated to dominate the age-related macular degeneration (AMD) disease market
The dry age-related macular degeneration segment is expected to dominate the global age-related macular degeneration (AMD) disease market with 67.70% market share because of growing geriatric population and the launch of new treatment methods for dry AMD.
- Based on end user, the global age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others.
The hospitals segment of end user segment is anticipated to dominate the wearable conferencing technology market
Hospitals segment is expected to dominate the market with a 55.22% market share. This segment is specialized in conducting numerous surgical intervention and have large professional’s portfolio for giving proper treatment. Moreover, high-quality diagnostic services in a safe healthcare environment are appropriate for consulting healthcare institutions to outsource large number of diagnostics tests for better customer services.
- Based on distribution type, the global age-related macular degeneration (AMD) disease market is segmented into direct tender, retail sales and others. The retail sales segment is expected to dominate the market with 64.33% market share because they are the main source of procurement of surgical and diagnostic devices and therapies by speciality clinics and healthcare organizations. The procurement of products by retail sales is highly convenient and cost-effective for healthcare providers.
Reconstructive surgeries is expected to dominate the global age-related macular degeneration (AMD) disease market with 30.30% market share because of growing number of procedures and surgeries.
Major Players
Data Bridge Market Research recognizes the following companies as the major age-related macular degeneration (AMD) disease market players in age-related macular degeneration (AMD) disease market Loop Road Holdings LLC (U.S.), Old Saw Mill Holdings LLC (U.S.), OSMR LLC (U.S.), Regeneron Capital International B.V. (Netherlands) and Regeneron International Limited (Ireland).
Market Development
- In 2022, Genentech, Inc. declared that the U.S. Food and Drug Administration had approved Vabysmo (faricimab-svoa) to treat wet DME and AMD. This will aid the company in commercializing the product in the global market during the forecast period
Regional Analysis
Geographically, the countries covered in the age-related macular degeneration (AMD) disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in age-related macular degeneration (AMD) disease market during the forecast period 2023 to 2030
North America dominates the age-related macular degeneration (AMD) disease market owing to the presence of favorable reimbursement policies and well-developed healthcare infrastructure in this region. Furthermore, increasing healthcare expenditure and government support will further enhance the market growth in this region.
Asia-Pacific is estimated to be the fastest-growing region in age-related macular degeneration (AMD) disease market the forecast period 2023 to 2030
Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 due to the large number of hospitals and diagnostic labs in this region. Additionally, the expansion of access to health care in highly populated countries such as India, China, and South Korea will further boost the market growth in this region.
For more detailed information about age-related macular degeneration (AMD) disease market report, click here – https://www.databridgemarketresearch.com/reports/global-age-related-macular-degeneration-amd-disease-market
